// App-Quantinova.ai

5536 : Preliminary results from the first in human study of activin-A inhibitor, STM434, in patients with granulosa cell ovarian cancer and other advanced solid tumors.

Researchers

Presenter

  • David Michael Hyman

Principal Investigators

  • Drew W. Rasco

  • Jeffrey R. Infante

  • Joyce F. Liu

  • Esther Welkowsky

  • Dung Luong Thai

  • Christopher M. Haqq

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • START-South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX

  • Sarah Cannon Research Institute, Nashville, TN

  • Dana-Farber Cancer Institute, Boston, MA

  • Atara Biotherapeutics, Westlake Village, CA

  • Atara Biotherapeutics, South San Francisco, CA

  • Atara Pinta Santa Maria Biotherapeutics, Newbury Park, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Gynaecological cancer

Biomarkers

  • N/A

Drug/Treatment

  • STM 434

Outcome

  • Unknown

Study Design

  • Pharmacokinetics

  • Dose Escalation

  • First-In-Human

Phase

  • NA

Study Id's

  • NCT02262455

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved